Skip to content

Dimerix chief Nina Webster on the potential multi-billion dollar market for DXB’s FSGS kidney treatment

This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Source Stockhead

Articles you might be interested in

Scroll To Top